Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders


Author index

Page Path
HOME > Browse Articles > Author index
Hyeeun Shin 1 Article
Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia
Jinyoung Youn, Hyeeun Shin, Ji Sun Kim, Jin Whan Cho
J Mov Disord. 2012;5(1):1-4.
  • 9,074 View
  • 92 Download
  • 6 Crossref
AbstractAbstract PDF
Background and Purpose:

Multiple system atrophy with predominant cerebellar ataxia is a disabling neurologic disease. However, effective management has not yet been established. We conducted a short-term, open-label preliminary study to assess the benefits of intravenous amantadine treatment in patients with probable multiple system atrophy with predominant cerebellar ataxia.


Twenty patients (10 male, 10 female) with probable multiple system atrophy with predominant cerebellar ataxia received 400 mg of amantadine by intravenous per day for 5 days. Ataxia severity was evaluated by the International Cooperative Ataxia Rating Scale before and after intravenous amantadine therapy and all subjects reported subjective improvement after intravenous amantadine treatment using a patient global impression scale. We analyzed the total and subscale scores by the ataxia scale and patient global impression scale.


The mean age was 57.4 years (range: 47–72) and the mean disease duration was 30.8 months (range: 11–79). The ataxia severity significantly decreased after intravenous amantadine therapy from 42.5 to 37.3 (p < 0.001). The mean patient global impression scale for improvement was 2.9 and there were no side effects of intravenous amantadine treatment observed. When we assessed responders, the duration of intravenous amantadine effect was more than 1 month in 4 subjects of 7 responders.


Our findings suggest that intravenous amantadine treatment can be a safe management option in cerebellar ataxia, although the mechanism is unclear. Thus, further double-blind, long-term studies with a larger sample size are needed.


Citations to this article as recorded by  
  • Low Dose Amantadine and Escitalopram in Progressive Supranuclear Palsy and Multiple System Atrophy
    Porimita Chutia, Shailendra Mohan Tripathi
    Annals of Neurosciences.2024;[Epub]     CrossRef
  • Amantadine withdrawal in a patient with spinocerebellar ataxia
    Andrew Pak, Emiley Chang
    BMJ Case Reports.2023; 16(11): e256840.     CrossRef
  • M1 and Cerebellar tDCS for MSA-C: a Double-Blind, Randomized, Sham-Controlled, Crossover Study
    Jong Hyeon Ahn, Dongyeong Lee, Minkyeong Kim, Jin Whan Cho, Won Hyuk Chang, Jinyoung Youn
    The Cerebellum.2022; 22(3): 386.     CrossRef
  • Effects of preoperative intravenous amantadine sulfate infusion on wake up test duration and postoperative opioid consumption in adolescents undergoing spine corrective surgery
    Ghada M. Aboelfadl, Saeid Elsawy, Belal O. Elnady, Rasha Hamed
    Perioperative Care and Operating Room Management.2021; 24: 100166.     CrossRef
  • Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19
    E.A. Katunina
    Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(4): 101.     CrossRef
  • Efficacy of Parenteral Amantadine Therapy in the Treatment of Multiple System Atrophy With Predominant Parkinsonism
    Adit Friedberg, Ilana Erikh, Maria Nassar, Elliot Sprecher, Ilana Schlesinger
    Clinical Neuropharmacology.2018; 41(5): 160.     CrossRef

JMD : Journal of Movement Disorders Twitter